Eli Lilly R&D chief Jan Lundberg heads for the exit as CEO assembles a new team at the top
A day after the FDA approved abemaciclib, new Eli Lilly CEO Dave Ricks has tapped several new chiefs for the pharma giant’s executive committee. And the change-out includes the departure of R&D chief Jan Lundberg as Ricks promotes Dan Skovronsky as the new head of science and technology and president of Lilly Research Labs.
Lundberg has been a central figure at Lilly over the last 8 years, a crucial period that saw out the end of John Lechleiter’s career at the top and the beginning of a stream of new drug approvals that are central to its longterm success. It hasn’t always been pretty, but the R&D group has kept its eyes on changing standards of care in cancer, diabetes and other diseases that have seen some big developments in the recent past.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.